Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Cromodata

Argentine marketplace turning de-identified records from a 47–84-facility Latin American network into research- and AI-ready clinical datasets.

Buenos Aires, Argentina, Latin AmericaHealthTech, Health data / real-world dataProbably Startup World Cup Argentina 2026 (Buenos Aires, 5–7 August 2026, organized by Startup Grind Buenos Aires; Cromodata's participation not confirmed)
Stage
Pre-seedNo documented AI
Product
On the marketFirst customers
Funding raised
$1.2Mdisclosed
Founded
20242 years ago
Founders
3Keila, Matías…
Global score
4.8Grade DRank 48 of 151

Overview

Argentine healthtech that runs a marketplace for de-identified clinical data for research and AI training, in partnership with dozens of hospitals (claimed network of 47 hospitals and 19M medical images).

Traction

First customers

Marketplace in operation. claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil); no data buyer publicly named.

Market

Real-world evidence solutions / health data

Pharma, medtech and AI developers need diverse real-world data, and Latin America is underrepresented in global datasets. Hospitals hold fragmented records but lack the means to de-identify and standardise them. Marketplaces monetise data through licences, with revenue shared with providers. Regulation in each country and trust are critical.

Addressable market

2025
$5.4B
2030
$10.8B
+14.8% a year

Real-world evidence solutions / health data: $5.42bn in 2025, +14.8%/year, $10.83bn in 2030 (MarketsandMarkets).

Customers

Pharma/CROs, medtech and AI developers (buyers, none named); hospitals and imaging centres (suppliers)

Who signs the cheque

Pharma RWE/medical affairs, AI product leads at medtech companies, CROs

Geographies

  • Argentina
  • Uruguay
  • Mexico
  • Dominican Republic
  • Brazil

Drivers

  • Demand for diverse training data for medical AI
  • RWE use in drug development and regulatory decisions
  • Hospitals seeking new revenue

Headwinds

  • Health-data regulation across five countries
  • Unproven monetisation (no buyer named)
  • Data-quality and re-identification risks

MarketsandMarkets puts RWE solutions at $5.42bn in 2025 and $10.83bn in 2030 (CAGR 14.8%); publisher range $2.0–20bn depending on scope.

Scalability 7/10. Data marketplace with network effects (more hospitals = more buyers), held back by each country's data protection regulations.

Market source: barchart.com

Technology

Category

Health data infrastructure / marketplace

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

A pipeline de-identifies and standardises fragmented clinical records (imaging, oncology) into usable datasets with secure access. Data comes from a hospital network across five countries.

Moat

Moderate: hospital network agreements and data volumes create network effects; pipelines can be replicated.

Differentiation

Focus on underrepresented Latin American populations and imaging.

Integration points

  • Hospital PACS/EHR
  • AI developers' training pipelines
  • Trial design and site feasibility
  • Data security/audit tools

Depends on

  • Hospital data-sharing agreements
  • Country privacy regulation
  • Buyer trust in de-identification

Use of AI

No use of AI mentioned

Product in detail

Pipeline for de-identifying and standardizing fragmented clinical records (imaging, oncology) into usable datasets, with secure access.

Business

Model
Data licensing marketplace with revenue sharing (inferred).
Revenue logic
Per-dataset licence or subscription.
Go-to-market
Hospital partnerships plus buyer outreach; Endeavor and Draper programmes.

Next milestones

  1. First named data buyers
  2. Seed close
  3. Brazil and Mexico expansion

Key risks

  • No named buyer
  • Regulation
  • Data quality

Opportunities

5 found in the network

Concrete moves for Cromodata inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 3
  • Co-development 1
  • Investors 1

Customers3

Who could buy, or sell through

Supply Latin American skin images for model training and validation

Legit.Health's CE-marked dermatology AI needs diverse skin types for performance and bias validation. Cromodata's imaging-rich network can supply de-identified, labelled datasets, giving Cromodata a named buyer and Legit.Health data for LatAm expansion.

35%confidence

Evidence from the records

  • “Computer vision and deep learning on skin images, CE-marked as a medical device, with automated severity scores and a clinical data platform.”
  • “claimed network of 47 hospitals and 19M medical images”
If it works
A first data licence and a case study for AI buyers.
First step
Send Legit.Health a dataset spec sheet and sample statistics.

Trial-design and site-feasibility data for BILIX's AKI programme

BILIX is preparing a phase 2b for cardiac-surgery AKI and needs incidence and site data. Cromodata can deliver feasibility counts from its hospital network.

25%confidence

Evidence from the records

  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
  • “Marketplace in operation: claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil); no data buyer publicly named.”
If it works
A pharma-type data contract and possible trial sites in LatAm.
First step
Propose a feasibility query to BILIX.

Provide hemoglobin-linked data to validate anemia AI

Monere's smartphone anemia screening needs validation against lab values in diverse populations. Cromodata's records can provide linked lab data.

20%confidence

Evidence from the records

  • “NiADA app (analysis of a smartphone photo of the lower eyelid) available on Google Play and Apple TestFlight; MIT Solve 2024 selection (30/2,200); no user figures or named pilot.”
  • “Pipeline for de-identifying and standardizing fragmented clinical records (imaging, oncology) into usable datasets, with secure access.”
If it works
A validation dataset and a second AI buyer.
First step
Ask Monere what data it needs for validation.

Co-development1

An integration or joint product

Certify datasets as leak- and poison-free

Buyers of AI training data will require assurance against re-identification and contamination. Hardshell scans datasets for these risks; a 'verified' label increases Cromodata's price and trust.

35%confidence

Evidence from the records

  • “"Data-centric" AI security platform that detects vulnerabilities, poisoning and leaks in training datasets.”
  • “High risk: health data regulation in 5 countries and unproven monetization.”
If it works
Higher buyer conversion through a security certificate.
First step
Run a joint scan on one dataset.

Investors1

A fund whose thesis fits

Pitch Wayra for the seed round via Legit.Health

Wayra invests at seed/Series A across Europe and Latin America, matching Cromodata's seed and expansion to Brazil and Mexico. It backed Legit.Health in the network.

30%confidence

Evidence from the records

  • “Mutua Madrileña (Mutua Ventures), Wayra (Telefónica), Grupo Ribera, business angels”
  • “Seed (announced, not closed)”
If it works
A corporate investor with LatAm reach.
First step
Ask Legit.Health for an introduction to Wayra.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Buenos Aires biotech fund and company builder backing pre-seed and seed Latin American life-science startups.

Argentine real-world health data at pre-seed — home city/country; data is complementary to biotech R&D but not a biology platform.

35%confidence

Evidence from the records

  • “Argentine biotech fund and company builder”
  • “Health data / real-world data”
  • “Marketplace in operation: claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil)”
Intro path
Founder-to-founder intro via Nanogrow Biotech (network portfolio company of GridX).
First step
Position RWD as infrastructure for LatAm biotech trials.

Latin American VC raising a $30M fund for regional startups with a focus on Peru; early backer of Reevalua.

Argentine real-world-data marketplace across 5 LatAm countries; Peru not yet covered and no data buyer named.

30%confidence

Evidence from the records

  • “Health data / real-world data”
  • “Argentina, Uruguay, Mexico, Dominican Rep., Brazil”
First step
Approach once a Peruvian clinic network is signed.

Argentine VC that invested in Nanogrow Biotech's US$1.2M seed; thesis and ticket otherwise undocumented.

Argentine real-world health data marketplace at pre-seed with US$1.2M raised: home-country health science, but data rather than biotech.

30%confidence

Evidence from the records

  • “Health data / real-world data”
  • “Argentina”
Intro path
Nanogrow Biotech (ATGen portfolio)
First step
Ask Nanogrow for an intro to ATGen.

ENISA: Spain's public lender to innovative startups and SMEs, providing participative loans of €25,000-1.5M with no personal guarantees.

Argentine health-data marketplace: Spanish-speaking, but eligibility requires a Spanish domicile.

5%confidence

Evidence from the records

  • “Health data / real-world data”
  • “Argentina”
First step
Only with a Spanish subsidiary.

Investment analysis

4.8D

Grade D

Rank 48 of 151

Disruption5.0/10
Business model4.0/10
Market6.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Relevant thesis but monetization not demonstrated: speculative.

Disruption

5/10

Marketplace for de-identified clinical data in Latin America: existing model (RWD) applied to an underserved region.

Business model

4/10

Claimed network of 47 to 84 facilities, no data buyer named.

Market

6/10

Score 6/10: TAM $5.42bn → base 5; scalability 7/10 (0); hospital network in 5 Latin American countries (+1).

Risk

7/10

Lower is better

High risk: health data regulation in 5 countries and unproven monetization.

Strengths

  • Multi-country hospital network
  • Strong demand for data for AI

Risks

  • Health data regulatory risk
  • No buyer named

Funding

$1.2M, disclosed
  1. 2025-09

    Pre-seed (first round)US$1.2M

    PharmStars Ventures (lead), Sancus Capital, Gabriela Pittis (business angel) — according to earlier sources; Forbes mentions "funds from Boston and Spain"

  2. à venir

    Seed (announced, not closed)not disclosed

    goal: expansion into Brazil and Mexico (Forbes)

Amount used in the study. $1.2M pre-seed; announced seed not closed, excluded.

Note. ≈ US$1.2M

Details added on the Argentine regional (dates, organizer); no direct link with Cromodata found; no new funding round found.

Team

  • Keila Barral Masri

    Co-founder (CEO)

    Founder inspired by her own 7-year diagnostic odyssey; selected for Endeavor Argentina's WE 2025 program and the Draper University program.

  • Matías Karlsson (spelling uncertain: "Carson" in the Forbes standfirst)

    Co-founder

    Co-founder cited by Forbes Argentina; background not specified.

  • Juan Pablo Merea (spelling uncertain: "Brea" in the Forbes standfirst)

    Co-founder

    Co-founder cited by Forbes Argentina; background not specified.

Sources

Regional final
Probably Startup World Cup Argentina 2026 (Buenos Aires, 5–7 August 2026, organized by Startup Grind Buenos Aires; Cromodata's participation not confirmed)
Identification confidence
high
  1. 1forbesargentina.com/negocios/la-emprendedora-convirtio-una-odisea-medica-soluci
  2. 2iproup.com/startups/61116-firma-argentina-usa-ia-y-datos-medicos-para-
  3. 3infonegocios.info/nota-principal/asi-funciona-cromodata-la-startup-que-creo-e
  4. 4cromodata.com/
  5. 5startupgrind.com/events/details/startup-grind-buenos-aires-presents-startup-

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet